This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PPTA Applauds Preserving Access To Orphan Drugs Acts

ANNAPOLIS, Md., June 14, 2013 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies.

Representative Jim Gerlach (R-PA), introduced H.R. 2315 with lead cosponsor Rep. Richard Neal (D-MA), and Senator Patrick Toomey (R-PA), introduced an identical bill, S. 1128, with lead cosponsors Sens. Robert Casey (D-PA) and Mike Crapo (R-ID). "Representative Gerlach and Senator Toomey have demonstrated exceptional leadership and commitment to the rare disease community with this legislation," Julie Birkofer, PPTA Senior Vice President, North America said.

The budget neutral bills will clarify the orphan drug exclusion from the annual pharmaceutical fee by basing the exclusion on whether the therapy is solely approved for marketing by the Food and Drug Administration (FDA) to treat a rare disease or condition. Under current law, a product only is excluded from paying the annual fee if it has claimed the Orphan Drug Act tax credit. This has left many plasma protein therapies unable to qualify for the exclusion and disproportionately affects these lifesaving rare disease therapies. In the U.S., a rare disease or condition is generally defined as one affecting less than 200,000 persons.

"Claiming of the Orphan Drug Act tax credit is not the best way to define all rare disease therapies; many are left out of the exclusion despite treating orphan conditions," Birkofer said. "The optimal way to meet the needs of patients who rely on PPTs is to clarify the provision in the Affordable Care Act to recognize rare diseases and this bill achieves that," she added.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs